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AbstrACt
Introduction In view of the increasing occurrence of both 
obesity and heart failure, a growing overlap of these two 
clinical entities in the near future is expected. Significant 
advances in our understanding of the pathophysiological 
consequences of obesity for the cardiovascular system 
have been made over the past two decades. However, to 
optimise management and treatment of obesity patients, 
further research is required to improve early identification 
of cardiac dysfunction in obesity and to gain insight in the 
underlying pathophysiology. The CARdiac Dysfunction In 
OBesity – Early Signs Evaluation (CARDIOBESE) study has 
been designed to address these issues.
Methods and analysis CARDIOBESE is a cross-sectional 
multicentre study of 100 obesity patients scheduled 
for bariatric surgery (body mass index (BMI) ≥35 kg/
m2) without known cardiovascular disease, and 50 age-
matched and gender-matched non-obese controls (BMI 
<30 kg/m2). Echocardiography, blood and urine biomarkers 
and Holter monitoring will be used to identify parameters 
that are able to show cardiac dysfunction at a very early 
stage in obesity patients (primary objective). Furthermore, 
a prospective follow-up study of obesity patients before 
and 1 year after bariatric surgery will be done to gain 
insight in the pathophysiology of obesity causing cardiac 
dysfunction (secondary objective).
Ethics and dissemination The study was approved 
by the Medical Ethics Committee Toetsingscommissie 
Wetenschappelijk Onderzoek Rotterdam e.o. (TWOR). 
Inclusion of patients and controls is almost complete. 
Analyses of the investigations are currently being 
performed, and dissemination through peer-reviewed 
publications and conference presentations is expected 
from the first quarter of 2019. By identifying early markers 
of cardiac dysfunction in obesity, and by understanding the 
underlying pathophysiology of the abnormalities of these 
markers, the CARDIOBESE study may provide guidance for 
risk stratification, monitoring and treatment strategies for 
obesity patients.
IntroduCtIon 
In view of the increasing occurrence of both 
obesity and heart failure, a growing overlap of 
these two clinical entities in the near future is 
expected.1–3 A body mass index (BMI) ≥30 kg/
m2 worsens the prognosis of patients with 
cardiovascular disease and doubles the life-
time risk of developing heart failure. Signif-
icant advances in our understanding of the 
pathophysiological consequences of obesity 
for the cardiovascular system have been made 
over the past two decades.4 5 Obesity is associ-
ated with diabetes mellitus, dyslipidaemia and 
hypertension. However, the onset of heart 
failure in obesity cannot be fully explained by 
the presence of these traditional cardiac risk 
factors.6 Also, BMI may not be the optimal 
parameter to reflect increased cardiovascular 
risk in obesity.7 
strengths and limitations of this study
 ► The CARdiac Dysfunction In OBesity – Early Signs 
Evaluation (CARDIOBESE) study will be the first study 
in which (speckle tracking) echocardiography, blood 
and urine biomarkers and Holter monitoring will be 
combined in a cohort of obesity patients and non-
obese controls in order to identify subclinical cardiac 
dysfunction in obesity patients (primary objective).
 ► Relating findings of the diagnostic techniques for 
assessment of cardiac dysfunction used in the 
CARDIOBESE study to specific features of obesity 
and by comparing results in obesity patients before 
and 1 year after bariatric surgery may help to gain 
insight in the pathophysiology of obesity causing 
cardiac dysfunction (secondary objective).
 ► A multidisciplinary approach with cardiologists, 
surgeons, internists and clinical epidemiologists 
being involved in the design and execution of the 
CARDIOBESE study will warrant optimal results and 
interpretation of the data.
 ► Only including obesity patients scheduled for bar-
iatric surgery may potentially lead to selection bias, 
preventing reliable extrapolation of results to all 
obesity patients.
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Present-day guidelines recommend screening of obesity 
patients on presence of cardiac risk factors and inclu-
sion of obesity patients in cardiovascular rehabilitation 
programmes directed to reduce body weight and increase 
physical activity, thereby improving cardiac risk factors.5 
The enormous and still growing prevalence of obesity 
warrants efficient screening of obesity patients with the 
highest need for such further risk assessment, follow-up 
and treatment. Current knowledge on the role of obesity 
in causing cardiac dysfunction is insufficient to optimally 
develop such strategies for obesity patients.
The aim of the CARdiac Dysfunction In OBesity – 
Early Signs Evaluation (CARDIOBESE) study is to iden-
tify subclinical cardiac dysfunction in obesity patients by 
echocardiography, blood and urine tests and/or Holter 
monitoring (primary objective).
Bariatric surgery has proven to be a successful therapy 
for severe obese patients, both regarding weight loss and 
reduction of traditional cardiac risk factors.8 Relating 
findings of the diagnostic techniques for assessment of 
cardiac dysfunction used in the CARDIOBESE study to 
specific features of obesity and by comparing results in 
obesity patients before and 1 year after bariatric surgery 
may help to gain insight in the pathophysiology of obesity 
causing cardiac dysfunction (secondary objective).
To the best of our knowledge, the CARDIOBESE study 
will be the first study in which (speckle tracking) echocar-
diography, blood and urine biomarkers and Holter moni-
toring will be combined in a cohort of obesity patients 
and non-obese controls.
MEthods And AnAlysIs
study design
Recruitment and inclusion of 100 consecutive obesity 
patients will take place at the bariatric surgery outpatient 
clinics of the Franciscus Gasthuis & Vlietland (75 patients) 
and Maasstad Ziekenhuis (25 patients). Fifty non-obese 
controls will be recruited using advertisements in a 
local newspaper or will be personnel recruited from 
the participating hospitals or family members or friends 
of personnel. Cardiologists of the Erasmus University 
Medical Centre with extensive expertise on early detec-
tion of cardiac dysfunction were involved in the design of 
the study and will be assisting in data analysis.
Primary objective
A cross-sectional study of obesity patients scheduled for 
bariatric surgery and age-matched and gender-matched 
non-obese controls will be performed to quantify the 
proportion of early signs of cardiac dysfunction in obesity 
patients and to determine if obesity patients have an 
elevated prevalence of cardiac dysfunction. Conventional 
and advanced echocardiography will be performed, 
blood and urine samples will be collected and a Holter 
monitor will be affixed for 24 hours heart rhythm regis-
tration (figure 1).
Secondary objective
A prospective follow-up study of the obesity patients 
undergoing bariatric surgery will be performed to 
gain insight in the pathophysiology of obesity causing 
cardiac dysfunction (figure 1). The aforementioned 
diagnostic techniques will be repeated 1 year after 
bariatric surgery. Before–after changes in parameters 
of cardiac structure and function (table 1) will be 
related to before–after changes in features of obesity 
(table 2).
The objective of the CARDIOBESE study is not to 
investigate specific effects of bariatric surgery. To fulfil 
the secondary objective, we also could have chosen a 
conservative approach for weight loss (diet and exercise 
Figure 1 Overview of the design of the CARDIOBESE study. CARDIOBESE, CARdiac Dysfunction In OBesity – Early Signs 
Evaluation.
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programme) or study the effects of naturally occur-
ring changes in weight. In the CARDIOBESE study, 
bariatric surgery is just used as an efficient method 
to rapidly induce significant metabolic improvement 
and weight loss. By studying these changes and trying 
to relate them to improvement in cardiac function, 
we expect to gain insight in the pathophysiology of 
obesity causing cardiac dysfunction. In this context, 
for the secondary objective, the obesity patient can 
be compared with his or her own baseline values and 
therefore be his or her own control.
study population
Inclusion criteria
Patients: BMI ≥35 kg/m2, scheduled for bariatric surgery, 
aged 35–65 years and written informed consent.
Controls: BMI <30 kg/m2, age 35–65 years and written 
informed consent.
Exclusion criteria
Patients and controls: history of cardiovascular disease.
Endpoints
The main study parameter is the proportion of patients/
controls with any sign of cardiac dysfunction as assessed 
by either echocardiography, blood/urine biomarkers 
or Holter monitoring (table 1). An early sign of cardiac 
dysfunction is considered to be present when a studied 
parameter is significantly different from a well-defined 
cut-off value.9 10 When such a cut-off value is not available, 
a studied parameter is considered to be an early sign of 
cardiac dysfunction when significantly different between 
obesity patients and non-obese controls. Secondary 
endpoints are: change in the proportion of obesity 
patients with any sign of cardiac dysfunction between 
study onset and 1 year after bariatric surgery and changes 
in cardiac dysfunction parameters in obesity patients 
undergoing bariatric surgery between study onset and 
1 year after surgery.
sample size calculation
The fact that the combination of parameters that we will 
use to identify subclinical cardiac dysfunction has not 
been investigated in obesity before complicates a well-de-
fined and evidence-based sample size calculation.
A conservative estimate would be that cardiac dysfunc-
tion based on conventional echocardiography is present 
in 20% of obesity patients and 2.5% of age-matched 
and gender-matched non-obese controls.11 Given these 
estimates, to be able to reject the null hypothesis that 
cardiac dysfunction rates are equal between patients and 
controls, at least 97 obesity patients and 49 non-obese 
controls have to be included in the analysis (alpha: 0.05 
(two sided), power: 0.80, 2:1 ratio of patients:controls). 
The use of more sensitive techniques in the CARDIOBESE 
study may increase the proportion of non-obese controls 
with an early sign of cardiac dysfunction. Nevertheless, 
the proportion of obesity patients with an early sign of 
cardiac dysfunction is expected to increase even more, 
assuring that the previous sample size calculation will still 
suffice.
study procedures
Echocardiography
Two-dimensional greyscale harmonic images will be 
obtained in the left lateral decubitus position using 
a commercially available ultrasound system (EPIQ 7, 
Philips, Best, The Netherlands), equipped with a broad-
band (1-5MHz) X5-1 transducer. All acquisitions and 
measurements will be performed according to current 
guidelines.9 10 12
Table 1 Parameters of cardiac structure and function
Echocardiography Holter monitoring
Blood and urine 
biomarkers
LV ejection fraction Premature atrial 
beats
High-sensitive 
troponin I
LV diastolic function Premature 
ventricular beats
Brain natriuretic 
peptide (BNP)
E/Em Atrial fibrillation
Septal Em Supraventricular 
tachycardia
Lateral Em Ventricular 
tachycardia
Left atrial volume 
index
Heart rate 
variability
LV mass (area–length 
method)
  SDNN
TAPSE   SDNN index
Pulsed tissue 
Doppler S wave 
tricuspid annulus
  rMSSD
Global systolic LV 
strain/strain rate*
  PNN50
Diastolic strain rate, 
early peak and late 
peak*
  Triangle
LV twist†   HF(norm)
  LF(norm)
  VLF Other biomarkers 
will be chosen in a 
later phase.
*Longitudinal, circumferential and radial strain will be measured.
†Peak systolic twist/twist velocity, peak diastolic untwist velocity 
and untwisting rate will be measured.
E/Em, ratio of peak early left ventricular filling velocity (E) over 
average septal and lateral mitral annulus early diastolic wave 
velocity (Em); HF(norm), high frequency normalised; LF(norm), low 
frequency normalised; LV, left ventricular; PNN50, percentage of 
successive normal sinus RR intervals >50 ms; rMSSD, root mean 
square of the successive normal sinus RR interval difference; 
SDNN, SD of all NN intervals; SDNN index, mean of the SD of 
all NN intervals for all 5 min segments of the entire recording; 
TAPSE, tricuspid annular plane systolic excursion; Triangle, number 
of all NN intervals/maximum number; VLF, very low frequency 
normalised.
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Interobserver and intraobserver, and test–retest repro-
ducibility of the assessment of cardiac dimensions and 
function in obesity by echocardiography will be investi-
gated in a substudy.
Blood and urine biomarkers
Blood and urine samples will be taken both for the study 
and as part of regular care. Urine supernatant, serum, 
citrate plasma and EDTA plasma will be prepared by 
centrifugation at 4°C and frozen in aliquots at −80°C for 
future analysis within 2 hours. In addition to the regular 
care path blood tests, high sensitive troponin I, C reactive 
protein and brain natriuretic peptide will be determined 
immediately. Other biomarkers may be selected later and 
can subsequently be determined from the stored blood 
and/or urine samples.
Holter monitoring
Heart rhythm will be recorded for 24 consecutive hours 
using a portable digital recorder (GE SEER Light, 
Chicago, Illinois, USA). The digital recorder will be 
connected using stickers that are placed on the chest.
statistical analysis
The proportion of obesity patients/non-obese controls 
with any sign of cardiac dysfunction will be compared 
as prevalence difference (95% CI) and prevalence ratio 
(95% CI). The unpaired Student’s t-test for continuous 
variables will be used to compare parameters with normal 
distributions, the non-parametric Mann-Whitney U test 
for continuous parameters with skewed distributions and 
the χ2 test/Fisher’s exact test for categorical variables. 
Statistical significance is considered as a two-tailed p value 
<0.05. Bonferroni correction for multiple testing will be 
applied. For each individual test parameter, presence/
absence of a sign of cardiac dysfunction will be evalu-
ated using multiple linear and logistic regression analysis 
(method: backwards stepwise analysis). Covariates to be 
included are the matching factors (age and gender), 
group definition (obesity patient/non-obese control), 
baseline characteristics considered to be potentially 
related to cardiac dysfunction (continuous variables such 
as BMI and body weight and categorical variables such 
as diabetes, hypertension, hyperlipidaemia and smoking) 
and other studied parameters identified to be significantly 
different between obesity patients and healthy volunteers 
by univariate analysis.
The change in the proportion of obesity patients with any 
sign of cardiac dysfunction between study onset and 1 year 
after bariatric surgery will be tested with the McNemar test. 
Multiple logistic regression analysis will be used to inves-
tigate which parameters contribute to the likelihood of a 
sign of cardiac dysfunction at 1 year after bariatric surgery. 
Covariates to be included are the same as mentioned before. 
Changes in individual parameters of cardiac dysfunction 
between study onset and 1 year after bariatric surgery will 
be studied using paired Student’s t-test, the non-parametric 
Wilcoxon signed rank test and McNemar test. Statistical 
analyses will be performed with SPSS V.25.0 or higher.
Patient and public involvement
Before the finalisation of the protocol for the 
CARDIOBESE study, 25 obesity patients that visited the 
outpatient clinic for screening for bariatric surgery were 
asked whether they would be willing to undergo some 
Table 2 General characteristics and obesity parameters
Physical examination Comorbidity Medication Laboratory tests
Body mass index Diabetes mellitus Beta blocker CRP Transferrin
Waist circumference Hypertension ACE inhibitor HbA1C Ferritin
Systolic BP Hyperlipidaemia ARB TSH Active Vitamin B12
Diastolic BP Current smoking Diuretic HDL-cholesterol Folic acid
Heart rate COPD Calcium-channel antagonist LDL-cholesterol Albumin
OSAS Statin Triglycerides Magnesium
Arthralgia Aspirin Total cholesterol Vitamin B1
Alcohol abuse Other antiplatelet Lipoprotein A Vitamin B6
Drug abuse Insulin Apo B100 Vitamin D
Oral antidiabetics Sodium Haemoglobin
Anti-inflammatory agents Potassium Haematocrit
Calcium Erythrocytes
Creatinine MCV
MDRD Leukocytes
ALAT Thrombocytes
Comorbidity as reported by the patient or the general practitioner. 
ALAT, alanine amino-transferase; ARB, angiotensin receptor blocker; BP, blood pressure; COPD, chronic obstructive pulmonary disease; CRP, 
C reactive protein; HbA1c, Glycosylated Hemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; MDRD, modification of diet 
in renal disease; OSAS, obstructive sleep apnoea syndrome; TSH, Thyroid-stimulating hormone.
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extra tests (echocardiogram, extra blood samples and 
Holter monitoring) when asked to participate in a study 
to investigate early signs of cardiac dysfunction in obesity. 
Without exception patients confirmed willingness to 
potentially participate. Patients recognised the impor-
tance of such a study and a majority of patients even 
reported that fear of developing heart disease was one of 
the major reasons to consider bariatric surgery.
On completion of the study, the results will be summarised 
in layman’s terms and distributed to participants and patient 
support groups. We will also promote the transfer of knowl-
edge to the general public (eg, including short, user-friendly 
articles/briefings in relevant newsletters, magazines and 
periodicals and user groups/forums).
dIsCussIon
Obesity is becoming a global epidemic.13 Beyond being 
related to an unfavourable cardiovascular risk factor profile, 
obesity also directly affects heart structure and function.14 
However, proper clinical evaluation of obesity patients may 
be hampered by the morphology of the patient.15 Also, 
knowledge on the exact pathophysiology of obesity causing 
cardiac dysfunction is limited.16 The CARDIOBESE study 
has been designed to address these issues.
Early signs of cardiac dysfunction in obesity
Echocardiography
It is well known that there is a relationship between obesity 
and left ventricular (LV) diastolic dysfunction (online 
supplementary appendix 1). However, the latest improve-
ment in echocardiography regarding early recognition of 
cardiac dysfunction has been the development of speckle 
tracking echocardiography. Each region of the myocar-
dium has its own unique speckle pattern that remains 
stable enough to permit spatial and temporal image 
processing by dedicated software packages, allowing 
assessment of myocardial deformation parameters such 
as LV strain and twist, which are well-known measures of 
subtle LV dysfunction.10 12 17
Speckle tracking echocardiography data in obesity 
patients are relatively scarce and only concern LV strain 
and not twist (online supplementary appendix 1). 
Although availability of speckle tracking echocardiog-
raphy may still be limited, echo-machines from all well-
known vendors are currently routinely equipped with 
speckle tracking software. Also, the technique has been 
significantly improved the past decennium, and inter-
vendor differences have been minimised,12 optimising 
clinical applicability. In the CARDIOBESE study, LV strain 
and twist will be thoroughly studied in obesity patients.
Blood and urine biomarkers
Focus in obesity research has mainly been on biomarkers 
of inflammation, insulin resistance and kidney/liver 
damage. Exploration of the value of blood and urine 
biomarkers for detection of subclinical cardiac dysfunc-
tion in obesity patients has been limited. There are some 
studies in which high-sensitive troponin T was measured 
in obesity patients but with conflicting results.18 19
Studies concerning natriuretic peptides in obesity 
patients without known cardiovascular disease demon-
strated that higher BMI is associated with lower circu-
lating natriuretic peptide concentrations (online 
supplementary appendix 1).20 21 The mechanism of this 
inverse relationship is not fully understood. It is thought 
to be related to either decreased production or increased 
peripheral metabolism of natriuretic peptides.22 Despite 
its inverse relationship with BMI, natriuretic peptides do 
provide significant prognostic information regarding the 
risk of developing heart failure in obesity.23
In the CARDIOBESE study, blood and urine biomarkers 
will be compared with echocardiography and Holter 
monitoring parameters in order to assess the diagnostic 
value of the biomarkers and to better understand the 
underlying pathophysiology of changes in the concen-
tration (or presence) of the biomarkers. Because of the 
rapid development of new blood and urine biomarkers 
of cardiac dysfunction, spare samples from each patient 
and control will be stored in order to choose optimal 
biomarkers at a later stage.
Holter monitoring
In community and population-based cohort studies, 
obesity has consistently emerged as a risk factor for 
atrial fibrillation.24 Identification of precursors of atrial 
fibrillation may lead to early detection of atrial fibrilla-
tion. Frequent premature atrial complexes are known 
to be associated with a risk of developing atrial fibrilla-
tion.25 Despite this, the usefulness of searching for atrial 
fibrillation or its electrical precursors as early markers 
of cardiac dysfunction in obesity has never been investi-
gated. Therefore, this will be done in the CARDIOBESE 
study.
Obesity patients have an increased sympathetic nervous 
system activity shown by an increase in mean heart rate, 
whereas heart rate variability parasympathetic indicators 
are decreased.26 Since autonomic dysfunction may play 
a role in development of cardiac dysfunction, in the 
CARDIOBESE study parameters of heart rate variability 
will be investigated.
Pathophysiology of cardiac dysfunction in obesity
The pathophysiology of cardiac dysfunction in obesity is 
incompletely understood and most likely multifactorial. 
Myocardial lipotoxicity, thrombosis, altered endothelial 
function, compression by fat tissue, diastolic dysfunc-
tion, increased afterload and filling pressures may all play 
a role.27 Changes in cardiac parameters after bariatric 
surgery have been studied before, showing improvement 
of LV structure, LV diastolic function, LV global strain 
and strain rate, natriuretic peptide levels and heart rate 
variability (online supplementary appendix 1). However, 
in none of these studies information from echocardiog-
raphy, blood and urine biomarkers and Holter moni-
toring have been combined. In the CARDIOBESE study, 
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correlating findings of these different diagnostic tech-
niques and comparing results before and 1 year after 
bariatric surgery may help to gain insight in the patho-
physiology of obesity causing cardiac dysfunction.
Ethics and dissemination
Inclusion of patients and controls is almost complete. 
CARDIOBESE enrolled 92 obesity patients between 
1 January 2017 and 23 July 2018, and 46 non-obese controls 
between 20 November 2017 and 23 July 2018. Analyses 
of the investigations are currently being performed, 
and dissemination through peer-reviewed publications 
and conference presentations is expected from the first 
quarter of 2019. By identifying early markers of cardiac 
dysfunction in obesity, and by understanding the under-
lying pathophysiology of the abnormalities of these 
markers, the CARDIOBESE study may provide guidance 
for risk stratification, monitoring and treatment strategies 
for obesity patients.
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